Show simple item record

Ras Signaling in Tumor Initiation and Maintenance

dc.contributor.advisor Counter, Christopher
dc.contributor.author Ancrile, Brooke
dc.date.accessioned 2008-08-01T12:53:20Z
dc.date.available 2011-07-26T04:30:03Z
dc.date.issued 2008-04-22
dc.identifier.uri https://hdl.handle.net/10161/666
dc.description.abstract <p>The Ras proteins, composed of H, N, and KRas, are a family of small GTPases that normally transmit extracellular cues to the cell in a regulated manner. However, Ras is commonly mutated to be inappropriately activated in human cancers, promoting a vast array of tumor phenotypes. Activation of the Raf, PI3K, and RalGEF Ras effector pathways is required to promote Ras-mediated tumorigenesis, leading not only to cell autonomous tumor phenotypes, but also the establishment of a tumor microenvironment. However, following tumor initiation, the requirement upon oncogenic Ras signaling is reduced to activation of PI3K, most likely due to a contribution of the tumor microenvironment. In order to further delineate the requirements for oncogenic Ras signaling pathways during tumorigenesis, I sought to 1) identify PI3K-independent factors necessary for tumor initiation, and 2) determine how PI3K activation maintains tumor growth in the absence of oncogenic Ras. Using cell-based assays and tumorigenesis assays in mice, I have shown that interleukin-6 (IL-6) is secreted upon induction of Ras expression, is required for Ras-mediated tumor initiation, and promotes tumorigenesis in a paracrine manner by fostering angiogenesis. Additionally, I have shown that eNOS, a downstream target of the PI3K pathway, is required for Ras-induced tumor initiation and maintenance, and, moreover, that eNOS-mediated S-nitrosylation and activation of wildtype Ras proteins is required throughout tumorigenesis. Pancreatic cancer is the cancer most highly associated with oncogenic Ras mutations, and I have shown that both IL-6 and eNOS are required for the tumorigenic growth of pancreatic cancer cell lines in mice. I therefore suggest that these proteins, perhaps in combination with other Ras inhibitors, may provide potential anti-cancer targets for oncogenic-Ras driven cancers in the clinic.</p>
dc.format.extent 74441606 bytes
dc.format.mimetype application/pdf
dc.language.iso en_US
dc.subject Biology, Genetics
dc.title Ras Signaling in Tumor Initiation and Maintenance
dc.type Dissertation
dc.department Genetics and Genomics
duke.embargo.months 24


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record